Temporal trends in mortality involving chronic lower respiratory disease and chronic kidney disease: evidence from CDC WONDER, 1999–2023 Authors: Ahmed Javed, Hammad Khan, Waleed Ahmad, Muhammad Uzair, Quratulain Ashraf, Muhammad Raafay Jamil, Muhammad Salman, FNU Aisha, Areesha Nawaz, Muhammad Abdul Haseeb Khan, Fatima Javid Published: 2026 ABSTRACT BackgroundChronic Lower Respiratory Disease (CLRD) and chronic kidney disease (CKD) are comorbid progressive diseases that have, over the decades, significantly contributed to high mortality rates. The overlapping mechanisms are aggravated by their coexistence, thus resulting in a poorer prognosis. The purpose of the study is to examine countrywide mortality rates related to CLRD and CKD and to identify the disparities among various population groups.MethodsThe CDC WONDER database was used to discuss age-adjusted mortality rates (AAMRs) of CLRD among patients with chronic kidney disease aged 25 and older, in 1999–2023, by sex and race, by geography, and by metropolitan status. Joinpoint regression was used to calculate Average Annual Percentage Changes (AAPCs) and Annual Percentage Changes (APCs) per 100,000 with 95% confidence intervals (CI).ResultsThere were 242,665 deaths among CKD patients with CLRD between 1999 and 2023. The age-adjusted mortality rate (AAMR) increased from 2.53 (95% CI: 2.46–2.61) in 1999 to 5.07 (95% CI: 4.99–5.16) in 2023, with an overall AAPC of 3.11% (95% CI: 1.91–4.32; p < 0.001). Men had higher AAMRs throughout the study period (AAPC: 2.04%; p = 0.002), while women showed a steeper increase over time (AAPC: 4.26%; p < 0.001). Among racial groups, non-Hispanic Whites had the highest mortality rates (AAPC: 3.62%; p < 0.001). The highest mortality burden was observed in individuals aged ≥ 85 years (AAPC: 4.93%; p < 0.001). Geographically, the Midwest region showed significant increases (AAPC: 3.52%; p < 0.001), with higher mortality observed in non-metropolitan areas (AAPC: 4.20%; p < 0.001).ConclusionThe documented gaps highlight the need to improve healthcare policies, eliminate gaps in coverage, and propagate education and awareness to decrease mortalities. The reduction of the mortalities is essential through addressing the inequalities in healthcare access and increasing health initiatives.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05067-w. Introduction Chronic diseases are currently the leading causes of death in the world and are increasingly putting increasing strains on health care systems globally [1]. In this regard, CLRDs (including COPD and asthma) and chronic kidney disease (CKD) are highly important due to their widespread prevalence and extremely devastating impacts on the survival and quality of life of patients [2]. Chronic kidney disease is a serious public health problem characterized by a slow and irreversible decline in kidney functionality. It continues to increase throughout the world, partly due to the ageing population and the increased prevalence of diabetes and hypertension [3]. Mortality rates among people having CKD, especially those developing to ESRD (End Stage Renal Disease), are greatly higher than the rate of the healthy population, mostly because of high cardiovascular issues [4]. Dialysis, which is the most common treatment of ESRD, leads to such complications as cardiovascular pressure and a long-term condition of systemic inflammation [5]. In the meantime, chronic lower respiratory illnesses, such as COPD, are also a significant contributor to morbidities as well as a primary cause of death throughout. According to the World Health Organization (WHO), CLRDs were ranked the fourth leading cause of death in the world in 2021 [6]. Chronic inflammation, oxidative damage, and slow airway narrowing are the core of all CLRDs that cause a severe disability, acute exacerbations, and heightened mortality risk [7]. Even though these two organ systems have been historically studied as distinct entities, there is recent evidence to indicate that the relationship between renal and pulmonary functions is complex and two-way. Several interrelated pathophysiological mechanisms could explain the high risk of mortality due to CLRD among patients with CKD: Systemic Inflammation is regarded as significant in this respect. CKD is considered a pro-inflammatory state characterized by elevated concentrations of circulating cytokines such as IL-6 and TNF-α. These can aggravate the underlying chronic inflammation in CLRD [5, 8]. Uremic Lung also belongs to our discussion. The uremic toxins in CKD can cause pulmonary complications that include: edema, pleural effusions, and the rise in capillary permeability. The conditions are capable of destroying gas exchange and respiratory functions significantly among patients with existing CLRD [9]. A very important part of this discussion is the comorbidities. Risk factors, in particular cardiovascular diseases, may impose simultaneous physiological loads on both renal and respiratory systems, thereby aggravating dysfunction in each of them [10]. Although these biological links are logical, the exact mortality burden of CLRD among patients with CKD is not yet explained well. Previous studies have been largely focused on deaths occurring directly due to cardiovascular events and, therefore, may have ignored the deaths that occurred due to respiratory problems, and that respiratory problems can also be a main cause of death [4, 11]. Now, it is important to quantitatively assess the relation between CKD and CLRD-related mortalities. This study will look into this knowledge gap by systematically assessing the incidence and risk factors for deaths occurring due to chronic lower respiratory disease in a well-defined cohort of patients with chronic kidney disease. The findings from this study could help make better combined care plans, promote educating the community about regular check-ups for lung abnormalities, and help the people who are at high risk live a more disease-free life years. Methods Study setting and population This retrospective, population-based study utilized data from the Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database to evaluate mortality trends associated with chronic lower respiratory diseases (CLRD) with coexisting chronic kidney disease (CKD) in the United States from 1999 to 2023 [12]. This database is a national death surveillance system, comprising complete data of death certificates of all 50 states and the District of Columbia [13]. Data abstraction Data were extracted from the CDC WONDER database using predefined query parameters for the period 1999–2023. Mortality records were identified using the Multiple Cause-of-Death (MCD) dataset. The year of collection of data was 1999 to 2023. Records were included if both CLRD and CKD codes appeared anywhere within the death certificate, regardless of whether either condition was listed as the underlying or contributing cause of death. Chronic lower respiratory diseases (CLRD) were identified using the International Classification of Diseases, Tenth Revision (ICD-10) codes J40–J47, which include bronchitis (J40–J42), emphysema (J43), chronic obstructive pulmonary disease (J44), asthma (J45–J46), and bronchiectasis (J47) [14]. Chronic kidney disease (CKD) was identified using the ICD-10 code N18, encompassing all stages of CKD [15]. Data was divided on the basis of the variables, Age group, Sex, Race, Place of death, States, Urban-rural classification, and Census regions. Age was restricted to individuals ≥ 25 years and categorized into seven ten-year groups (25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and ≥ 85 years). However, due to small counts and data suppression in the CDC WONDER database, estimates for the 25–34 age group were considered unreliable in stratified analyses and were therefore excluded from subgroup-specific analyses, while remaining included in overall estimates. Sexes included were male and female. The races were NH White, NH Black, Hispanic, NH Asian or Pacific Islander, and Non-Hispanic American Indian or Alaska Native. Geographic areas comprised all the states and the District of Columbia in the U.S. Each stratum of demographics and each year was comprehensively analyzed in the database to obtain the number of deaths, the crude mortality rate, and the age-adjusted mortality rate (AAMR) per 100,000 of the U.S. standard population. CDC WONDER did age-adjustment by the direct method by using the year 2000 U.S. standard population and adjusting the age to remove the potential effects of varying distribution of age over time and to enable valid comparisons across years [16]. This ICD-10–based approach using CDC WONDER follows standardized methodologies described in prior epidemiological and trend analyses [12, 17, 18]. Statistical analysis Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the direct standardization method, standardized to the 2000 U.S. standard population. Corresponding 95% confidence intervals (CIs) and standard errors were computed using methods established by the National Center for Health Statistics [17, 18]. Joinpoint regression analysis was performed using the Joinpoint Regression Program (Version 5.2.0, National Cancer Institute)following standard methodologies described by the National Cancer Institute. The method models trends by fitting a sequence of linked straight-line segments on a logarithmic scale and detects points (joinpoints) at which the annual rate of change varies significantly. The analysis calculated Annual Percent Change (the slope for each segment between joinpoints), and Average Annual Percent Change (AAPC, a total measure of trend for the entire 1999–2023 period, measured as a weighted average of the APCs). All analyses were considered statistically significant when the p-value was below 0.05. AAPCs within demographic subgroups (e.g., sex, race/ethnicity) were compared using the pairwise comparison option within the Joinpoint software to check for differences in mortality trends and discover which population is much healthier and which is not [18]. This analysis was done by using the already available studies that linked the CLRD with renal disease to present the national trends in CLRD mortality connected with CKD, emphasizing the populations most affected over the last 25 years [10, 19]. Results Between 1999 and 2023, a total of 242,665 deaths were attributed to chronic kidney disease (CKD) and chronic lower respiratory disease (CLRD) among U.S. adults. The overall age-adjusted mortality rate (AAMR) increased from 2.53 (95% CI: 2.46–2.61) in 1999 to 5.07 (95% CI: 4.99–5.16) in 2023. Joinpoint regression demonstrated a significant upward trend, with an average annual percent change (AAPC) of 3.11% (95% CI: 1.91–4.32; p < 0.001) (Fig. 1). Fig. 1Age-adjusted mortality rate due to chronic lower respiratory disease and chronic kidney disease in the United States, 1999–2023 Age-adjusted mortality rate due to chronic lower respiratory disease and chronic kidney disease in the United States, 1999–2023 Sex-specific trends Men consistently exhibited higher mortality rates than women throughout the study period. From 1999 to 2023, mortality rates increased in both sexes. Among Men, AAMR increased from 4.17 (95% CI: 4.01–4.32) in 1999 to 6.20 (95% CI: 6.05–6.34) in 2023, with an AAPC of 2.04% (95% CI: 0.80–3.30; p = 0.002). Similarly, among women, AAMR increased from 1.58 (95% CI: 1.50–1.66) in 1999 to 4.27 (95% CI: 4.17–4.37) in 2023, with a higher AAPC of 4.26% (95% CI: 2.93–5.62; p < 0.001). Although men had consistently higher mortality rates, women experienced a more rapid relative increase over time, resulting in a narrowing sex gap in recent years (Fig. 2). Fig. 2Age-adjusted mortality rate caused by chronic lower respiratory disease and chronic kidney disease stratified by sex in the United States, 1999–2023 Age-adjusted mortality rate caused by chronic lower respiratory disease and chronic kidney disease stratified by sex in the United States, 1999–2023 Race-specific trends Marked disparities in mortality were observed across racial and ethnic groups. Non-Hispanic White individuals accounted for the largest proportion of deaths (n = 201,307) and experienced a significant increase in mortality, with AAMRs increasing from 2.51 (95% CI: 2.43–2.60) in 1999 to 5.60 (95% CI: 5.50–5.70) in 2023, with an AAPC of 3.62%; 95% CI: 2.34–4.93; p < 0.001). Among non-Hispanic Black or African American individuals, AAMRs increased from 3.43 (95% CI: 3.13–3.73) in 1999 to 5.50 (95% CI: 5.21–5.78) in 2023, with a significant AAPC of 2.32% (95% CI: 0.93–3.73; p = 0.002). In contrast, Hispanic or Latino individuals demonstrated relatively stable mortality trends over time. AAMRs increased modestly from 1.86 (95% CI: 1.55–2.17) in 1999 to 2.16 (95% CI: 1.98–2.35) in 2023; however, this change was not statistically significant (AAPC 0.84%; 95% CI: −0.76–2.45; p = 0.291). Similarly, American Indian and Asian populations showed no significant change, with AAMRs ranging from 1.62 (95% CI: 1.25–2.07) in 1999 to 1.98 (95% CI: 1.76–2.20) in 2023 (AAPC − 0.09%; 95% CI: −1.80–1.66; p = 0.916). (Fig. 3). Fig. 3Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by race in the United States, 1999–2023 Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by race in the United States, 1999–2023 Age group-specific trends Mortality rates increased markedly with advancing age, demonstrating a strong age-dependent gradient. Across the study period, the highest crude mortality rates were consistently observed in older age groups, particularly among individuals aged ≥ 85 years, followed by those aged 75–84 years and 65–74 years. From 1999 to 2023, among the individuals aged 35–44 years, AAMR increased slightly from 0.08 (95% CI: 0.05–0.11) to 0.09 (95% CI: 0.07–0.13), with a non-significant trend (AAPC = 0.80; 95% CI: −0.32 to 1.94; p = 0.152), similarly, among the individuals aged 45–54 years, Rates increased from 0.34 (95% CI: 0.28–0.40) in 1999 to 0.49 (95% CI: 0.42–0.56) in 2023, with a significant upward trend (AAPC = 2.11; 95% CI: 1.05–3.18; p < 0.001). Among the individuals aged 55–64 years, Rates rose from 1.59 (95% CI: 1.43–1.75) in 1999 to 2.50 (95% CI: 2.35–2.65) in 2023 with an AAPC of 2.40% (95% CI: 1.14–3.67; p < 0.001). Among the individuals aged 65–74 years, Rates increased from 5.98 (95% CI: 5.63–6.34) in 1999 to 8.29 (95% CI: 7.99–8.59) in 2023 with an AAPC of 1.60% (95% CI: 0.33–2.90; p = 0.016). Among individuals aged 75–84 years, Rates increased substantially from 15.12 (95% CI: 14.43–15.81) in 1999 to 28.27 (95% CI: 27.50–29.04) in 2023 with an AAPC 2.88% (95% CI: 1.63–4.13; p < 0.001). Among the individuals aged ≥ 85 years, the highest mortality burden was observed, with rates rising from 23.76 (95% CI: 22.28–25.24) in 1999 to 74.75 (95% CI: 72.60–76.91) in 2023, representing the steepest increase (AAPC 4.93%; 95% CI: 3.48–6.40; p < 0.001). Overall, the magnitude and rate of increase in mortality were progressively greater with advancing age, with the most pronounced escalation observed in individuals aged ≥ 85 years (Fig. 4). Fig. 4Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality rate stratified by age group in the United States, 1999–2023 Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality rate stratified by age group in the United States, 1999–2023 Urbanization-specific trends Mortality rates increased significantly in both metropolitan and non-metropolitan areas over the study period. In metropolitan areas, AAMRs increased from 2.44 (95% CI: 2.36–2.53) in 1999 to 5.60 (95% CI: 5.50–5.69) in 2023, with an APC of 3.67 (95% CI: 2.03–5.33; p < 0.001). In non-metropolitan areas, a steeper rise was observed, with AAMRs increasing from 2.90 (95% CI: 2.72–3.09) in 1999 to 6.63 (95% CI: 6.39–6.87), corresponding to an AAPC of 4.20 (95% CI: 2.63–5.79; p < 0.001) (Fig. 5). Fig. 5Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by urban-rural classification in the United States, 1999–2023 Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by urban-rural classification in the United States, 1999–2023 Geographic region-specific trends By census region, from 1999 to 2023, mortality rates increased across all regions. In the Northeast, AAMR rose from 2.54 (95% CI: 2.38–2.70) in 1999 to 3.93 (95% CI: 3.76–4.10) in 2023. In the Midwest, rates increased from 2.84 (95% CI: 2.67–3.00) to higher levels in 2023. Similarly, in the South, AAMR increased from 2.50 (95% CI: 2.37–2.62) in 1999 to 5.10 (95% CI: 4.97–5.24) in 2023. In the West, mortality rates rose from 2.27 (95% CI: 2.11–2.43) to 4.87 (95% CI: 4.70–5.05) over the same period. Trend analysis demonstrated significant increases in all regions. The Midwest exhibited the highest rate of increase (AAPC = 3.52; 95% CI: 2.26–4.80; p < 0.001), followed by the South (AAPC = 3.22; 95% CI: 1.93–4.52; p < 0.001) and the West (AAPC = 3.21; 95% CI: 1.70–4.74; p < 0.001). The Northeast showed the lowest, yet still significant, increase (AAPC = 2.39; 95% CI: 1.28–3.51; p < 0.001) (Fig. 6). Fig. 6Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by Census region in the United States, 1999–2023 Chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality stratified by Census region in the United States, 1999–2023 Stratified by states At the state level, substantial geographic variation in age-adjusted mortality rates (AAMRs) was observed across the study period. Between 1999 and 2020, the highest mortality burdens were noted in states such as West Virginia (8.10), North Dakota (7.18), Kentucky (6.57), and Indiana (6.35), whereas comparatively lower rates were seen in Utah (2.17), Hawaii (2.32), Nevada (2.40), and Arizona (2.62). In the more recent period (2021–2023), an overall upward shift in AAMRs was evident across most states. The highest rates were reported in Oklahoma (11.51), West Virginia (11.03), Kentucky (10.99), Colorado (9.45), and Nebraska (9.42), indicating a marked escalation in mortality burden. Conversely, relatively lower AAMRs persisted in states such as Hawaii (2.64), New York (3.13), and New Jersey (3.29), although even these demonstrated increases compared to earlier years. (Fig. 7) Fig. 7Geographical representation of chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality rate stratified by states in the United States, a). 1999–2020, b). 2021–2023 Geographical representation of chronic lower respiratory disease and chronic kidney disease-related age-adjusted mortality rate stratified by states in the United States, a). 1999–2020, b). 2021–2023 Stratified by place of deaths From 1999 to 2023, the majority of deaths occurred in medical facilities, with inpatient settings accounting for the largest proportion (n = 97,274), followed by deaths at home (n = 60,308) and in nursing homes or long-term care facilities (n = 51,966). Hospice facilities contributed a smaller but notable proportion of deaths (n = 13,998), reflecting end-of-life care utilization. Deaths occurring in outpatient or emergency room settings were relatively limited (n = 10,064), while deaths classified as dead on arrival (n = 635) and those occurring in other locations (n = 7,980) represented minor proportions. A very small number of deaths had an unknown location status (n = 316). (Fig. 8). Fig. 8chronic lower respiratory disease and chronic kidney disease-related deaths mortality rate stratified by Place of Deaths in the United States, 1999–2023 chronic lower respiratory disease and chronic kidney disease-related deaths mortality rate stratified by Place of Deaths in the United States, 1999–2023 Discussion Chronic lower respiratory diseases (CLRD) are referred to as non-infectious conditions of the lungs and respiratory tract that affect the airways and other structures, excluding cancers and trauma [20]. Despite advancements in diagnostic and therapeutic approaches, pharmacotherapy, and substantial public health initiatives, the burden of CLRD persists. The high prevalence of this disease depicts the multifaceted etiology of the disease with some comorbid conditions and other risk factors including age, smoking, low socioeconomic status, and environment [21]. The CDC National Center of Health Statistics states that CLRD was the fifth major cause of death in the United States in 2023 [13, 22]. Simultaneously, chronic kidney disease, i.e., the terminal form of chronic kidney disease, has become one of the significant causes of disease burden in the United States and worldwide. According to the United States Renal Data System (USRDS), it has been reported that close to 37 million adults are living with CKD [24], and the prevalence has been on the increase as a result of ageing, especially when concomitant with cardiopulmonary diseases [23]. CKD further lead to the condition of endothelial dysfunction, systemic inflammation and oxidative stress, which worsens other chronic conditions, as well. Recent findings emphasize the bidirectional interdependency of chronic renal and pulmonary dysfunction known as the lung-kidney axis [24]. Fluid overload, metabolic acidosis, and anemia, the typical consequences of end-stage renal disease, in combination with oxidative stress, systemic inflammation and endothelial dysfunction, further worsen pulmonary gas exchange, and chronic hypoxia, hypercapnia, and exposure to nephrotoxic agents may also hasten end-stage renal disease [25]. Therefore, individuals with CKD and CLRD are the vulnerable population with high hospitalization, morbidity, and all-cause mortality rates [26]. The comorbidity of the two diseases is especially worrying because of the presence of shared risk factors, as cited above, that are concentrated in individuals of older age group and under-served groups [27]. Age is one of the most powerful and consistent risk factors of death among people with CLRD, especially when it comes to the cases of CKD as a comorbid condition. Aging is not merely about the progression in time but is a progressive impact on organ reserve and physiological resilience caused by environmental, biological, and behavioral elements. The level of mortality risk rises steeply in adulthood and peaks in old age in the context of epidemiological analysis. Mortality data provided by CDC WordPress, Multiple Cause of Death (1999–2023), reveal that there has been a sharp rise in mortality due to CLRD in the age group of 25 to 85 years. After the age of 45, the risk becomes higher, and the sharpest gradient is noted between 65 and 85 years [28]. This pattern was also the case with CKD. It is predominant in individuals who are over 65 years compared to those who are in the age range of 18–44 years [29]. This concurring trend of these two age-related diseases highlights the influence of aging on the development of multimorbidity and mortality. Pathophysiologically, it has been found that aging is also associated with the reduction of residual elastic recoil, chest wall compliance, and a slow loss of surface area and hence a decrease in ventilatory reserve [30]. The changes undermine respiratory efficiency and predispose individuals to respiratory diseases. Aging causes GFR to decline, through loss of nephrons and glomerulosclerosis, and GFR reduces by 0.75-1.0 ml/min/m2/year [31]. Alongside it, volume overload and acid-base imbalance due to renal defect worsen pulmonary congestion, whereas chronic hypoxemia and oxidative stress enhance renal injury [32]. Age, therefore, must be considered as a determinant of significance that contributes to changes over time and highlights the necessity to design chronic disease prevention strategies that target geriatric populations. Combined, these findings highlight age as a determinant of CLRD-CKD mortality and suggest the biological interface between aging and multimorbidity, which should be addressed by age-specific preventive and management decisions. Gender has affected mortality attributed to CLRD and CKD due to its multidimensional and intricate influence. Traditionally, CLRD and COPD in particular were largely seen in men, and in particular because of a higher rate of tobacco consumption and job exposures to respiratory toxins. The trend continued up to 1999 in the US. The mortality rate associated with COPD has since significantly reduced among men and the current epidemiological data sets reflect a significant change [33]. The modern analysis shows that there has been an increase in female CLRD mortality compared to that of men [34]. The Global Burden of Disease 2023 data show that the age-standardized rates have been on the decline in general, but the rate of decrease is lower in women and as a result, the distribution of CLRD mortality will be nearly equal between men and women in the U.S [35]. This disparity can be explained by biological and sociocultural differences. Airways are smaller, lung volumes are lower, and airway reactivity is higher in women than in men, and this could predispose them to the adverse consequences of tobacco smoke and air pollutants [36]. This is worsened by the increase in smoking among women in the mid-20th century to the late 20th century in the U.S. On the contrary, the risk of mortality due to CKD remains greater in men. Such variations are a manifestation of sex-specific biological and hormonal processes. Estrogen provides renoprotective benefits to women by increasing the functioning of the endothelium and reducing oxidative stress, thus increasing renal hemodynamics [37]. In contrast, testosterone worsens the damage in the kidneys by enhancing the generation of reactive oxygen species (ROS) and elevating the expression of the pro-inflammatory mediators. The differences support the necessity of sex specific interventions and fair access to preventive care. Racial and ethnic inequities are multifactorial determinants of health outcomes in the United States, especially with regard to high morbidity and mortality of diseases when two chronic conditions are present. Their impact is synergistic, boosting racial and ethnic disparities in health. Overall AAMR in individuals with coexisting CKD and CLRD has decreased at a slower rate between 1999 and 2023, and in populations, especially non-Hispanic Blacks and Hispanics, the rates have even leveled off and even slowly increased in most recent years [38]. These differences are the result of a complex network of pathophysiological processes and structural health determinants. These populations are more affected with hypertension, diabetes mellitus, and delayed access to preventive care in nephrology [39]. Black, Hispanic, and Native Americans have higher exposure to ambient air pollutants such as PM2.5, nitrogen oxides, and ozone-causing agents that lead to pulmonary and renal dysfunction [40]. Non-Hispanic whites people have the highest absolute CLRD-CKD mortality, which is more prevalent in smoking and the age distribution is older [41]. On the other hand, the lowest rates of mortality are observed among Asian American populations, which indicate better health cardiometabolic profiles and an earlier history of using healthcare services. Outside the individual-level, structural racism remains an underlying source of these inequalities. Inequity in policies regarding housing and employment, as Bailey et al. (2021) indicate, continues to expose some racial groups to the effects of chronic stressors and higher disease burden [42]. Finally, the racial and ethnic gaps underline that disease control should be treated not only through biomedical improvement and enhancement but also by means of dealing with social determinants. In the United States, mortality related to CKD and CLRD is bidirectionally related to living in a metropolitan area. On the one hand, urban areas have better healthcare and superior healthcare facilities. Conversely, the areas expose inhabitants to an increased level of pollutants, which leads to a decrease in kidney and lung functions [43]. These pollutants and socio-spatial inequities are compensated with the effects of chronic exposure to them. Thus, the association between urban living and CLRD-CKD mortality requires combined environmental and population health policies. Geographical heterogeneity is quite pronounced in the U.S. CDC Wonder data shows that the southeastern region and the Appalachian region have high mortality rates. The regions have higher exposure to air pollutants through coal and higher rates of obesity, hypertension and diabetes, which result in renal and pulmonary dysfunction [44]. The states of the Pacific Northwest and New England, on the other hand, have a lower mortality [45]. State-level inequality is therefore not only a geographical issue, but it signifies a system of risks that continues to take away the deaths, which are preventable both in the renal and respiratory realms. Overall, disparities of state-level status summarize the larger overlap of environment, socioeconomic, and policy-based determinants that represent the necessity of state-specific intervention throughout the states of the United States. Limitations This study has several limitations. First, the use of CDC WONDER mortality data relies on death certificate reporting, which is subject to misclassification and potential underreporting of both CKD and CLRD. Second, the analysis is based on ICD-10 coding, which may not capture disease severity or clinical nuances. Third, the ecological nature of the dataset precludes adjustment for individual-level factors such as smoking status, environmental exposures, or treatment patterns, limiting causal inference. Additionally, our classification of CLRD and CKD was listed on the death certificate, which may misjudge causal relationships, as the temporal sequence between conditions cannot be determined. Despite these limitations, the study’s strengths include its large, nationally representative dataset spanning over two decades and the use of standardized methods to assess temporal trends across multiple demographic strata. Conclusion In conclusion, mortality associated with coexisting CLRD and CKD has increased in the United States over the past two decades, with significant disparities across demographic and geographic groups. These findings underscore the growing burden of multimorbidity and highlight the need for integrated, equity-focused approaches to prevention and management. Addressing both clinical and structural determinants of health will be essential to reducing mortality in this high-risk population. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1